12.68 0.00 (0.00%)
After hours: 5:01PM EDT
|Bid||12.25 x 1000|
|Ask||12.77 x 800|
|Day's Range||11.66 - 12.81|
|52 Week Range||9.18 - 19.00|
|Beta (5Y Monthly)||2.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.75|
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -5.56% and 14.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.
Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.
CAMBRIDGE, Mass., Feb. 20, 2020 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting new data from two of its development programs at Keystone Symposia’s Engineering the Genome Conference, a joint meeting with the Emerging Cellular Therapies: Cancer and Beyond Conference, taking place Feb. 8-12, 2020, in Banff, Canada. Intellia researchers are presenting data in support of the company’s lead engineered cell therapy development candidate, NTLA-5001 for the treatment of the hematological cancer, acute myeloid leukemia (AML).
The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups.
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today provided an update on recent progress and the Company’s 2020 priorities and expected milestones. With milestones anticipated across our pipeline, we are making important progress towards the development of curative treatments for severe diseases.
Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.
Two of the industry’s leading gene-editing experts have unveiled their next venture: a gene-silencing startup called Triplet Therapeutics.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
After signing two back-to-back deals with Novartis this year, small Boston-based startup IFM Therapeutics is ramping up its business development with a new incubator.
CAMBRIDGE, Mass., Nov. 26, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
Axsome Therapeutics is on a tear this year - with shares skyrocketing over 3,000%. This comes as the biotech company's migraine drug posted successful results in a late-stage study. Yahoo Finance's Anjalee Khemlani joins Seana Smith on The Ticker to discuss.